Palisade Bio Stock EBITDA
| PALI Stock | USD 0.85 0.15 15.00% |
Palisade Bio fundamentals help investors to digest information that contributes to Palisade Bio's financial success or failures. It also enables traders to predict the movement of Palisade Stock. The fundamental analysis module provides a way to measure Palisade Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Palisade Bio stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -11.1 M | -11.6 M |
Palisade | EBITDA |
Palisade Bio Company EBITDA Analysis
Palisade Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Palisade Bio EBITDA | (12.28 M) |
Most of Palisade Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Palisade Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Palisade EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Palisade Bio is extremely important. It helps to project a fair market value of Palisade Stock properly, considering its historical fundamentals such as EBITDA. Since Palisade Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Palisade Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Palisade Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Palisade Ebitda
Ebitda |
|
According to the company disclosure, Palisade Bio reported earnings before interest,tax, depreciation and amortization of (12.28 Million). This is 101.4% lower than that of the Biotechnology sector and 112.26% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.32% higher than that of the company.
Palisade EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Palisade Bio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Palisade Bio could also be used in its relative valuation, which is a method of valuing Palisade Bio by comparing valuation metrics of similar companies.Palisade Bio is currently under evaluation in ebitda category among its peers.
Palisade Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Palisade Bio from analyzing Palisade Bio's financial statements. These drivers represent accounts that assess Palisade Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Palisade Bio's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 513.3M | 167.9M | 219.7M | 4.0M | 4.6M | 4.4M | |
| Enterprise Value | 512.5M | 162.9M | 220.4M | (8.0M) | (9.2M) | (8.8M) |
Palisade Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Palisade Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Palisade Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Palisade Bio's value.| Shares | Armistice Capital, Llc | 2024-12-31 | 105.4 K | Cetera Investment Advisers | 2024-12-31 | 70 K | Geode Capital Management, Llc | 2024-12-31 | 10.1 K | Ubs Group Ag | 2024-12-31 | 9 K | Tower Research Capital Llc | 2024-12-31 | 4.7 K | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 100.0 | Wells Fargo & Co | 2024-12-31 | 21.0 | Bank Of America Corp | 2024-12-31 | 10.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.0 | Jpmorgan Chase & Co | 2024-12-31 | 0.0 |
Palisade Fundamentals
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | (4.71 M) | ||||
| Shares Outstanding | 2.77 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 7.20 % | ||||
| Number Of Shares Shorted | 106.91 K | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.45 X | ||||
| Price To Sales | 14.03 X | ||||
| Revenue | 250 K | ||||
| EBITDA | (12.28 M) | ||||
| Net Income | (12.3 M) | ||||
| Cash And Equivalents | 5 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 369 K | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | 5.51 X | ||||
| Cash Flow From Operations | (11.13 M) | ||||
| Short Ratio | 0.96 X | ||||
| Earnings Per Share | (13.26) X | ||||
| Target Price | 20.0 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 2.97 M | ||||
| Total Asset | 14.05 M | ||||
| Retained Earnings | (121.51 M) | ||||
| Working Capital | 10.74 M | ||||
| Net Asset | 14.05 M |
About Palisade Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Palisade Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Palisade Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Palisade Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:Check out Palisade Bio Piotroski F Score and Palisade Bio Altman Z Score analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.